ADT

ADT

Androgen Deprivation Therapy (ADT), also known as hormone therapy, is a type of treatment primarily used to manage prostate cancer. ADT works by reducing the levels of androgens, male hormones, in the body, which can fuel the growth of prostate cancer cells. The most common androgens are testosterone and dihydrotestosterone (DHT).

Mechanism of Action

ADT can be achieved through several methods, including surgical removal of the testes (orchiectomy), which is a permanent form of ADT, or through the use of medications that either stop the production of androgens by the testes or block the action of androgens on their receptors. Medications used in ADT include Luteinizing Hormone-Releasing Hormone (LHRH) agonists, LHRH antagonists, and anti-androgens.

Indications

ADT is primarily indicated for the treatment of advanced prostate cancer, particularly in cases where the cancer has spread beyond the prostate gland (metastatic prostate cancer) or is at high risk of doing so. It is also used in combination with radiation therapy for intermediate to high-risk localized prostate cancer to improve outcomes.

Side Effects

The reduction of androgen levels can lead to several side effects, including hot flashes, reduced libido, erectile dysfunction, bone density loss, muscle mass loss, fatigue, and an increased risk of cardiovascular diseases and diabetes.

Controversies and Considerations

The use of ADT in treating prostate cancer is not without controversy. The potential side effects necessitate a careful consideration of the benefits and risks of this therapy. Ongoing research aims to optimize the timing and duration of ADT to maximize its benefits while minimizing adverse effects.

Future Directions

Research into ADT continues to evolve, with studies exploring intermittent ADT, which involves cycles of treatment followed by breaks, as a way to reduce side effects while still controlling the cancer. Additionally, new drugs and treatment combinations are being investigated to improve outcomes for patients with prostate cancer.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian